NewsRx

Search our medical news database

West Nile Virus

Study verifies viral inactivation from plasma-derived therapies

Published in Blood Weekly, December 19th, 2002

Baxter Healthcare Corporation presented the first data that verifies the inactivation of West Nile Virus (WNV) during the processes routinely used in the production of its plasma-derived therapeutics.

Baxter initiated the verification study to address the rising public concern over the perceived threat of transmission of WNV through use of plasma-derivatives. The study follows recent reports about increased incidence of WNV in the United States and the transmission of WNV through organ donations and blood transfusions.

These data were presented at a 2-day public workshop hosted by the U.S. Food and Drug Administration Center for Biologics Evaluation...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook